These limitations include relatively small numbers of patients with specific targetable alterations per tumor type, not including alterations other than KRAS mutations that can activate the MAPK pathway (as such alterations were not tested routinely in CLIA-certified laboratories), and various dose levels and various drugs used in the analyses, resulting in large tested hypotheses that cannot rule out false positive conclusions. This evidence concerns the gene KRAS and neoplasm.